Introduction to the Proteomics Roundtable Series
Standard BioTools Inc. (NASDAQ: LAB), headquartered in South San Francisco, has recently introduced an exciting initiative called the Proteomics Roundtable Series. This unique series of virtual events is aimed at igniting discussions centered around the swiftly advancing arena of proteomics, a field that is reshaping our understanding of healthcare. With expert speakers addressing significant innovations and applications in proteomics, this platform promises to be informative and engaging.
Kickoff Session: A New Perspective on Protein Measurement
The inaugural session titled Is More Really More? Evaluating the Case for High-Plex, High-Quality Proteomics is scheduled for an upcoming Friday. Stephen Williams, MD, PhD, the Chief Medical Officer at Standard BioTools, will lead a compelling discussion featuring prominent researchers involved in the EPIC cancer study, a vast project encompassing over 500,000 participants. These experts will unveil groundbreaking findings related to cancer developments that have been previously elusive due to limitations in protein measurement.
Featured Speakers
This session will include contributions from:
- Elio Riboli, MD, a distinguished Professor of Cancer Epidemiology at Imperial College London,
- Marc Gunter, PhD, who chairs the Cancer Epidemiology and Prevention department at the same institution,
- Karl Smith-Byrne, DPhil, a Senior Molecular Epidemiologist at the University of Oxford.
Their insights promise profound implications for the understanding and treatment of major cancers.
Future Sessions to Look Forward To
The excitement doesn’t end with the kickoff session. Future events in the Proteomics Roundtable Series are set to cover a diverse range of topics that are vital to researchers and healthcare providers:
Comparative Metrics for Proteomic Platforms
In this upcoming discussion, eminent proteomics scientists will navigate the differences in various proteomics platforms. Attendees can expect to gain deeper clarity on misconceptions regarding cross-reactivity and understand how these technologies stack up against each other in massive-scale studies.
Deployment of Proteomic Technologies
Another session will delve into how leading biobank researchers are translating complex proteomic data into actionable insights. With an emphasis on diverse populations, the conversation will highlight the importance of selecting the right platforms that prioritize throughput and reproducibility for impactful outcomes.
Proteomics in Drug Development
One particularly anticipated discussion will focus on the role of proteomics in accelerating drug development during clinical trials. Innovators within the biopharmaceutical sector, leveraging the SomaScan™ Assay, will share how they utilize proteomic insights to streamline the decision-making process and foster faster development of effective therapies.
Registration and Participation
For those interested in these critical discussions, registration is available through the Standard BioTools website. By signing up, participants can stay informed about all future updates regarding the series. Additionally, all sessions will be live-streamed on the Company’s Investor page and will be accessible for later viewing, ensuring everyone has the opportunity to engage with this transformative knowledge.
About Standard BioTools Inc.
Standard BioTools Inc. (NASDAQ: LAB) has established a renowned portfolio of next-generation technologies designed to empower biomedical researchers in developing innovative medical solutions more efficiently. As a leader in this sector, the company employs its proprietary technologies such as SomaScan, mass cytometry, and microfluidics to derive reliable and repeatable insights in various health and disease contexts. Through collaboration with academic and professional entities worldwide, Standard BioTools is dedicated to addressing pressing challenges in clinical and translational research across oncology, immunology, and more.
Frequently Asked Questions
What is the Proteomics Roundtable Series?
The Proteomics Roundtable Series is a collection of virtual events organized by Standard BioTools featuring discussions with experts about developments in proteomics.
Who will be speaking at the first session?
The first session will feature Stephen Williams, MD, PhD, along with speakers from the EPIC cancer study, including Elio Riboli, Marc Gunter, and Karl Smith-Byrne.
What topics will be covered in future sessions?
Future sessions will discuss comparative metrics for proteomic technologies, their deployment in biobanks, and their role in drug development.
How can I register for the events?
Individuals can register for the events through the Standard BioTools website, where updates will also be posted.
What does Standard BioTools focus on?
Standard BioTools focuses on developing technologies that enable faster and better medical research, particularly in areas like oncology and immunology.
